Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Equity Average (2021 - 2025)

Historic Equity Average for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $4.9 billion.

  • Roivant Sciences' Equity Average fell 1202.17% to $4.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.9 billion, marking a year-over-year decrease of 1202.17%. This contributed to the annual value of $5.4 billion for FY2025, which is 1772.37% down from last year.
  • Per Roivant Sciences' latest filing, its Equity Average stood at $4.9 billion for Q4 2025, which was down 1202.17% from $4.8 billion recorded in Q3 2025.
  • Roivant Sciences' 5-year Equity Average high stood at $6.5 billion for Q1 2024, and its period low was $1.3 billion during Q3 2023.
  • Moreover, its 5-year median value for Equity Average was $2.3 billion (2021), whereas its average is $3.5 billion.
  • In the last 5 years, Roivant Sciences' Equity Average crashed by 3709.38% in 2022 and then surged by 33144.03% in 2024.
  • Over the past 5 years, Roivant Sciences' Equity Average (Quarter) stood at $2.3 billion in 2021, then tumbled by 37.09% to $1.5 billion in 2022, then surged by 168.94% to $4.0 billion in 2023, then surged by 40.53% to $5.6 billion in 2024, then decreased by 12.02% to $4.9 billion in 2025.
  • Its last three reported values are $4.9 billion in Q4 2025, $4.8 billion for Q3 2025, and $5.0 billion during Q2 2025.